

9 November 2023

Dermatology and Respiratory new biologic and targeted medications

I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions:

Q1. How many patients were treated in September 2023 (or latest available month) by the Dermatology department with the following drugs:

- **Abrocitinib (Cibinqo)** <5
- **Baricitinib (Olumiant)** <5
- **Dupilumab (Dupixent)** 146
- **Omalizumab (Xolair)** 26
- **Tralokinumab (Adtralza)** <5
- **Upadacitinib (Rinvoq)** 22

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

Q2. How many patients were treated in September 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- **Benralizumab (Fasenra)** 98
- **Dupilumab (Dupixent)** 39
- **Mepolizumab (Nucala)** 235
- **Omalizumab (Xolair)** 21
- **Reslizumab (Cinqaero)** <5
- **Tezepelumab (Tezspire)** 0

Data supplied by Difficult Asthma team. Please note that due to limitations within service and health care at home we have not commenced any new patients on biologics since May 2023. We are working with the clinical team and pharmacy to seek additional capacity to commence new patients on biologics.